Ecstasy use and higher-level cognitive functions: Weak effects of ecstasy after control for potential confounds

Psychological Medicine

Volumn 38, Issue 9, 2008, Pages 1319-1330

  Bedi, G ^a,b   Redman, J ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cannabis; Cognition; Ecstasy; Memory; Polydrug

Indexed keywords

CANNABIS; ECSTASY; ILLICIT DRUG;

ADULT; ARTICLE; ATTENTION; COGNITION; DRUG USE; FEMALE; HUMAN; LIFESPAN; MALE; NEUROPSYCHOLOGICAL TEST; PREDICTION; REGRESSION ANALYSIS; SAMPLE SIZE; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

ADULT; AFFECT; ATTENTION; CANNABIS; COGNITION; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEMORY; MEMORY, SHORT-TERM; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STUDENTS; SUBSTANCE-RELATED DISORDERS; VERBAL BEHAVIOR;

EID: 48749095029     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291708002730     Document Type: Article

References (63)

1. Allott K, Redman J (2007). Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)? Neuroscience and Biobehavioral Reviews 31, 327-347.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press: Washington, DC.
3. Australian Crime Commission (2005). Illicit Drug Data Report 2003-2004. Australian Crime Commission: Canberra, Australia.
4. Back-Madruga C, Boone KB, Chang L, Grob CS, Lee A, Nations H, Poland RE (2003). Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clinical Neuropsychologist 17, 446-459.
5. Battaglia G, Yeh SY, De Souza EB (1988). MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacology, Biochemistry and Behavior 29, 269-274.
6. Beck AT, Steer RA (1993). Beck Anxiety Inventory Manual. The Psychological Corporation: San Antonio, TX.
7. Bedi G, Redman J (2006). Self-reported ecstasy use: the impact of assessment method on dosage estimates in recreational users. Journal of Psychopharmacology 20, 432-436.
8. Bedi G, Redman J (in press). Metamemory in recreational ecstasy polydrug users : what do selfreports of memory failures mean? Journal of Psychopharmacology.
9. Bhattachary S, Powell JH (2001). Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or 'ecstasy' : evidence for cognitive impairment. Psychological Medicine 31, 647-658.
10. Bolla KI, McCann UD, Ricaurte GA (1998). Memory impairment in abstinent MDMA ('Ecstasy') users. Neurology 51, 1532-1537.
11. Clemens KJ, Cornish JL, Li KM, Hunt GE, McGregor IS (2005). MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49, 195-207.
12. Cole JC, Sumnall HR, Grob CS (2002). Sorted : ecstasy facts and fiction. Psychologist 15, 464-467.
13. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH (2001). The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 153, 373-379.
14. Eaton WW, Smith C, Ybarra M, Muntaner C, Tien A (2004). Center for Epidemiologic Studies Depression Scale : review and revision (CESD and CESD-R). In The Use of Psychological Testing for Treatment Planning and Outcomes Assessment: Vol. 3 : Instruments for Adults (ed. M. E. Maruish), pp. 363-377. Lawrence Erlbaum Associates : Mahwah, NJ.
15. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ (2002). Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ('ecstasy') polydrug users. Psychopharmacology 162, 203-214.
16. Fox HC, Toplis AS, Turner JJD, Parrott AC (2001). Auditory verbal learning in drug-free ecstasy polydrug users. Human Psychopharmacology : Clinical and Experimental 16, 613-618.
17. Giancola PR, Tarter RE (1999). Executive cognitive functioning and risk for substance abuse. Psychological Science 10, 203-205.
18. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000). Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). Journal of Neurology, Neurosurgery and Psychiatry 68, 719-725.
19. Gouzoulis-Mayfrank E, Fischermann T, Rezk M, Thimm B, Hensen G, Daumann J (2005), Memory in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Drug and Alcohol Dependence 78, 317-323.
20. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J (2003). Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27, 819-827.
21. Gravetter FJ, Wallnau LB (2004). Statistics for the Behavioral Sciences, 6th edn. Wadsworth/Thomson Learning: Belmont, CA.
22. Halpern JH, Pope Jr. HG, Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D (2004). Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug and Alcohol Dependence 75, 135-147.
23. Hannon R, Adams P, Harrington S, Fries-Dias C, Gipson MT (1995). Effects of brain injury and age on prospective memory self-rating and performance. Rehabilitation Psychology 40, 289-298.
24. Hoshi R, Mullins K, Boundy C, Brignell C, Piccini P, Curran HV (2007). Neurocognitive function in current and exusers of ecstasy in comparison to both matched polydrugusing controls and drug-naïve controls. Psychopharmacology 194, 371-379.
25. Jacobsen LK, Mencl W, Pugh KR, Skudlarski P, Krystal JH (2004). Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: possible relationship to neurotoxic effects. Psychopharmacology 173, 383-390.
26. Jager G, de Win MM, Vervaeke HK, Schilt T, Kahn RS, van den Brink W, van Ree JM, Ramsey NF (2007). Incidental use of ecstasy : no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Psychopharmacology 193, 403-414.
27. Lamers CTJ, Bechara A, Rizzo M, Ramaekers JG (2006). Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. Journal of Psychopharmacology 20, 302-311.
28. Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS (2004). Neuropsychological Assessment, 4th edn. Oxford University Press: New York.
29. Kalechstein AD, De La Garza II R, Mahoney III JJ, Fantegrossi WE, Newton TF (2007). MDMA use and neurocognition : a meta-analytic review. Psychopharmacology 189, 531-537.
30. McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA (1999). Altered neuroendocrine and behavioral m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 147, 56-65.
31. McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994). Serotonin neurotoxicity after ±3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'): a controlled study in humans. Neuropsychopharmacology 10, 129-138.
32. Meyers JE, Meyers KR (1995). Rey Complex Figure Test (RCFT) and Recognition Trial. Psychological Assessment Resources: Odessa, FL.
33. Morgan MJ (1999). Memory deficits associated with recreational use of 'ecstasy' (MDMA). Psychopharmacology 141, 30-36.
34. Morgan MJ (2000). Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152, 230-248.
35. Ozgur O, Munir K (2005). Attentional and neurocognitive characteristics of high-risk offspring of parents with schizophrenia compared with DSM-IV attention deficit hyperactivity disorder children. Schizophrenia Research 76, 293-299.
36. Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW, Cowen PJ (1994). Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology 33, 575-588.
37. Parrott AC, Garnham NJ, Wesnes K, Pincock C (1996). Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours. Human Psychopharmacology : Clinical and Experimental 11, 391-400.
38. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998). Cognitive performance in recreational users of MDMA or 'ecstasy' : evidence for memory deficits. Journal of Psychopharmacology 12, 79-83.
39. Pope Jr. HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2001). Neuropsychological performance in longterm cannabis users. Archives of General Psychiatry 58, 909-915.
40. Pope Jr. HG, Yurgelun-Todd D (2004). Residual cognitive effects of long-term cannabis use. In Marijuana and Madness: Psychiatry and Neurobiology (ed. D. Castle and R. Murray), pp. 198-210. Cambridge University Press: New York.
41. Reneman L, Schilt T, De Win MML, Booij I, Schmand B, Van den Brink W, Bakker O (2006). Memory function and serotonin transporter gene polymorphism in ecstasy (MDMA) users. Journal of Psychopharmacology 20, 389-399.
42. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW (1988). ±3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. Journal of the American Medical Association 260, 51-55.
43. Riedel WJ, Klaassen T, Deutz NEP, van Someren A, van Praag HM (1999). Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology 141, 362-369.
44. Roiser JP, Rogers RD, Cook LJ, Sahakian BJ (2006). The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls. Psychopharmacology 188, 213-227.
45. Roiser JP, Rogers RD, Sahakian BJ (2007). Neuropsychological function in ecstasy users : a study controlling for polydrug use. Psychopharmacology 189, 505-516.
46. Ruff RM, Light RH, Parker SB, Levin HS (1996). Benton Controlled Oral Word Association Test : reliability and updated norms. Archives of Clinical Neuropsychology 11, 329-338.
47. Schilt T, de Win MML, Koeter M, Jager G, Korf DJ, van den Brink W, Schmand B (2007). Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Archives of General Psychiatry 64, 728-736.
48. Schmidt M (1996). Rey Auditory Verbal Learning Test : A Handbook. Western Psychological Services : Los Angeles, CA.
49. Simon NG, Mattick RP (2002). The impact of regular ecstasy use on memory function. Addiction 97, 1523-1529.
50. Spreen O, Strauss E (1998). A Compendium of Neuropsychological Tests : Administration, Norms and Commentary. Oxford University Press: New York.
51. Stafford J, Degenhardt L, Agaliotis M, Chanteloup F, Fischer J, Matthews A, Newman J, Proudfoot P, Stoove M, Weekley J (2004). Australian Trends in Ecstasy and Related Drug Markets 2004: Findings from the Party Drugs Initiative (PDI). National Drug and Alcohol Research Centre: Sydney, Australia.
52. Sumnall HR, Tyler E, Wagstaff GF, Cole JC (2004). A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers. Drug and Alcohol Dependence 76, 93-99.
53. Tabachnick BG, Fidell LS (2001). Using Multivariate Statistics, 4th edn. Allyn and Bacon: Boston, MA.
54. The Psychological Corporation (2001). Wechsler Test of Adult Reading (WTAR) Manual. The Psychological Corporation: San Antonio, TX.
55. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167, 85-96.
56. Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A (2006). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users : the longitudinal perspective. Journal of Psychopharmacology 20, 211-225.
57. Ward J, Hall K, Haslam C (2006). Patterns of memory dysfunction in current and 2-year abstinent MDMA users. Journal of Clinical and Experimental Neuropsychology 28, 306-324.
58. Wechsler D (1997). Wechsler Adult Intelligence Scale - Third Edition. The Psychological Corporation: San Antonio, TX.
59. Wilson BA, Alderman N, Burgess PW, Emslie H, Evans JJ (1996). Behavioural Assessment of the Dysexecutive Syndrome. Thames Valley Test Company: Bury St Edmonds, UK.
60. Wilson BA, Cockburn J, Baddeley AD, Hiorns R (1989a). The development and validation of a test battery for detecting and monitoring everyday memory problems. Journal of Clinical and Experimental Neuropsychology 11, 855-870.
61. Wilson MA, Ricaurte GA, Molliver ME (1989b). Distinct morphological classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 28, 121-137.
62. Yip J, Lee TMC (2005). Effects of ecstasy use on neuropsychological function: a study in Hong Kong. Psychopharmacology 179, 620-628.
63. Zakzanis KK, Campbell Z (2006). Memory impairment in now abstinent MDMA users and continued users : a longitudinal follow-up. Neurology 66, 740-741.